Pulse Biosciences Sells ElectroBlate Subsidiary
Ticker: PLSE · Form: 8-K · Filed: Mar 11, 2024 · CIK: 1625101
| Field | Detail |
|---|---|
| Company | Pulse Biosciences, Inc. (PLSE) |
| Form Type | 8-K |
| Filed Date | Mar 11, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: divestiture, strategic-shift, subsidiary-sale
TL;DR
Pulse Bio selling off ElectroBlate unit to focus on its main business.
AI Summary
Pulse Biosciences, Inc. announced on March 8, 2024, that it has entered into a definitive agreement to sell its ElectroBlate, Inc. subsidiary to an undisclosed buyer. The transaction is expected to close in the second quarter of 2024. This divestiture is part of Pulse Biosciences' strategic focus on its Cell & Tissue Solutions business.
Why It Matters
This sale allows Pulse Biosciences to streamline its operations and concentrate resources on its core Cell & Tissue Solutions business, potentially leading to improved financial performance and strategic growth in that area.
Risk Assessment
Risk Level: medium — The sale of a subsidiary can introduce financial and operational risks, and the lack of disclosed buyer information adds uncertainty.
Key Players & Entities
- Pulse Biosciences, Inc. (company) — Registrant
- ElectroBlate, Inc. (company) — Subsidiary being sold
- March 8, 2024 (date) — Date of report and agreement
- second quarter of 2024 (date) — Expected closing period
FAQ
What is the financial impact of selling ElectroBlate, Inc. on Pulse Biosciences, Inc.?
The filing does not disclose the sale price or specific financial terms of the transaction, so the immediate financial impact is not detailed.
Who is the buyer of ElectroBlate, Inc.?
The filing states that Pulse Biosciences, Inc. has entered into a definitive agreement to sell its ElectroBlate, Inc. subsidiary, but the buyer is not identified in this report.
When is the sale of ElectroBlate, Inc. expected to be completed?
The transaction is expected to close in the second quarter of 2024.
What is the strategic reason behind selling ElectroBlate, Inc.?
Pulse Biosciences, Inc. is divesting ElectroBlate, Inc. as part of its strategic focus on its Cell & Tissue Solutions business.
What business segment is Pulse Biosciences, Inc. focusing on after the sale?
Following the divestiture of ElectroBlate, Inc., Pulse Biosciences, Inc. will concentrate on its Cell & Tissue Solutions business.
Filing Stats: 439 words · 2 min read · ~1 pages · Grade level 10.2 · Accepted 2024-03-11 09:10:42
Key Financial Figures
- $0.001 — nge on Which Registered Common stock , $0.001 par value per share PLSE The Nasdaq
Filing Documents
- plse20240227_8k.htm (8-K) — 24KB
- ex_631554.htm (EX-99.1) — 13KB
- image1.jpg (GRAPHIC) — 20KB
- 0001437749-24-007278.txt ( ) — 199KB
- plse-20240308.xsd (EX-101.SCH) — 3KB
- plse-20240308_def.xml (EX-101.DEF) — 11KB
- plse-20240308_lab.xml (EX-101.LAB) — 15KB
- plse-20240308_pre.xml (EX-101.PRE) — 11KB
- plse20240227_8k_htm.xml (XML) — 3KB
01
Item 8.01 Other Events. On March 8, 2024, Pulse Biosciences, Inc. (the "Company") issued a press release announcing the FDA 510(k) Clearance for its CellFX nsPFA Percutaneous Electrode System. A copy of the Company's press release is attached as Exhibit 99.1.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release issued by Pulse Biosciences, Inc. dated March 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PULSE BIOSCIENCES, INC. Date: March 11, 2024 By: /s/ Kevin P. Danahy Kevin P. Danahy President and Chief Executive Officer (Principal Executive and Principal Financial Officer)